{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:04:41Z","timestamp":1788015881261,"version":"build-2784847793"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Idiopathic inflammatory myopathies (IIMs) encompass a diverse group of diseases characterized by considerable variability in clinical manifestations, antibody profiles, and responsiveness to immunosuppressive therapies. This study aimed to investigate the association between organ involvement and distinct myositis autoantibodies in individuals with IIM in a single-center cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with ICD diagnoses M33.1, M33.2, M33.9, or M609 who (1) had been tested with Euroline blot assay for myositis autoantibodies and (2) met the classification criteria of definite\/probable polymyositis (PM) or dermatomyositis (DM), anti-synthetase syndrome (ASS), or inclusion body myositis (IBM) were included. Medical journals were retrospectively examined with respect to clinical disease features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy patients (median age 58\u2009years; 66% females) were included and represented the following diagnosis: PM (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923), DM (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921), ASS (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923), and IBM (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093). Most of the patients (87%) presented a muscle biopsy indicative of myositis. The presence of autoantibodies was as follows: myositis-specific antibodies, MSA (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200953), myositis-associated antibodies, MAA (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200933), both MSA\u2009+\u2009MAA (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924), MSA only (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929), MAA only (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099), no MSA, or MAA (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098). Anti-Jo-1 was the most common MSA (19%), whereas the most common MAA was anti-Ro\/SSA52 (31%). We observed a significant association between antibody patterns and lung disease. In our cohort, 47% of the patients in the whole study group, 86% of patients with anti-SSA52, and 100% with anti-Jo-1 had pulmonary involvement. Patients with both MSA and MAA had a higher incidence of lung disease and decreased CO-diffusion capacity. This was especially prominent in anti-Ro\/SSA52-positive patients. Interestingly, none of the patients suffered from lung disease if only antibodies against Mi-2\u03b1, Mi-2\u03b2, NXP2, HMGCR, and TIF1\u03b3 were present or no MSA\/MAA were detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The simultaneous presence of both MAA and MSA indicates an increased risk of lung involvement in patients with inflammatory myopathies. The presence of any MAA, and especially anti-Ro\/SSA52, is associated with more severe pulmonary disease. Our data suggest that MAA antibodies might be relevant markers for early detection and treatment of lung involvement in IIM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2024.1340310","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T01:22:17Z","timestamp":1711588937000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Myositis-associated antibodies predict the severity of lung involvement in adult patients with inflammatory myositis \u2212 a cohort study of 70 adult patients with myositis in a single center"],"prefix":"10.3389","volume":"11","author":[{"given":"Josefin","family":"Marklund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balsam","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rille","family":"Pullerits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/joim.12524","article-title":"Diagnosis and classification of idiopathic inflammatory myopathies","volume":"280","author":"Lundberg","year":"2016","journal-title":"J Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3899\/jrheum.171325","article-title":"Complement consumption in systemic lupus erythematosus leads to decreased Opsonophagocytosis in vitro","volume":"45","author":"Mitander","year":"2018","journal-title":"J Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00296-009-0884-9","article-title":"Characteristics of interstitial lung disease in SS-A positive\/Jo-1 positive inflammatory myopathy patients","volume":"29","author":"V\u00e1ncsa","year":"2009","journal-title":"Rheumatol Int"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease","volume":"39","author":"la Corte","year":"2006","journal-title":"Autoimmunity"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/rheumatology\/kev300","article-title":"Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease","volume":"55","author":"Gunnarsson","year":"2016","journal-title":"Rheumatology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13075-023-03141-4","article-title":"Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study","volume":"25","author":"Hamberg","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2021.04.020","article-title":"Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases","volume":"91","author":"Decker","year":"2021","journal-title":"Eur J Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"105895","DOI":"10.1016\/j.rmed.2020.105895","article-title":"Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjogren syndrome","volume":"163","author":"Buvry","year":"2020","journal-title":"Respir Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2015-208093","article-title":"Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss","volume":"75","author":"Krishnamurthy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1084\/jem.177.4.905","article-title":"Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model","volume":"177","author":"Brouwer","year":"1993","journal-title":"J Exp Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1084\/jem.20041859","article-title":"Ro\/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block","volume":"201","author":"Salomonsson","year":"2005","journal-title":"J Exp Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1172\/JCI117025","article-title":"Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro\/SSA-positive patients in rabbit hearts","volume":"93","author":"Garcia","year":"1994","journal-title":"J Clin Invest"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1021\/bi962317a","article-title":"The sterol carrier protein-2 fatty acid binding site: an NMR, circular dichroic, and fluorescence spectroscopic determination","volume":"36","author":"Stolowich","year":"1997","journal-title":"Biochemistry"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s00296-011-1957-0","article-title":"Sonographic assessment of carpal tunnel syndrome in rheumatoid arthritis: prevalence and correlation with disease activity","volume":"32","author":"Karadag","year":"2012","journal-title":"Rheumatol Int"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00296-020-04745-8","article-title":"Carpal tunnel syndrome in patients with rheumatoid arthritis and psoriatic arthritis: an electrophysiological and ultrasonographic study","volume":"41","author":"Kaya Suba\u015f\u0131","year":"2021","journal-title":"Rheumatol Int"},{"key":"ref21","first-page":"195","article-title":"Early detection of neurological involvement in systemic lupus erythematosus patients","volume":"35","author":"Sivri","year":"1995","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000247422","article-title":"Carpal tunnel syndrome and systemic sclerosis","volume":"185","author":"Machet","year":"1992","journal-title":"Dermatology"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1340310\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T01:22:20Z","timestamp":1711588940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1340310\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":22,"alternative-id":["10.3389\/fmed.2024.1340310"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1340310","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"article-number":"1340310"}}